- 5 Cancelled Shows That Are Returning and 13 We Wish Would Come Back
- Donald Trump May Have Had His 'Oops' Moment Over Mexico
- Chinese Gold Standard Could Create 'Fireworks' - Bloomberg Intelligence
- MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin
- If Greece Leaves Eurozone, Here's What Will Happen to the World Economy
Jim Cramer likes Soutwest (LUV), isn't a fan of Sarepta Therapeutics (SRPT) and will soon have a 'surprise' piece on McDonald's (MCD).
07/01/15 - 02:40 PM EDT
Some biotech stocks way underperformed in this red-hot sector.
07/01/15 - 12:02 PM EDT
The biotech sector has been one of the fastest growing sectors through June 30, 2015. Here are the 10 best biotech stocks this year.
07/01/15 - 11:23 AM EDT
U.S. stocks opened higher on reports that Greek Prime Minister Alexis Tsipras sent a letter to European creditors agreeing to most conditions of a financing deal.
07/01/15 - 09:49 AM EDT
There's mostly one reason why insiders buy more shares of their companies: They think the shares are undervalued. So when they do, retail investors should pay attention.
07/01/15 - 10:20 AM EDT
- Tickers in this article:
Technical analysis shows the air is thinning rapidly in the biotech sector.
07/01/15 - 09:30 AM EDT
U.S. stock futures are bounding upward as investors maintain optimism that a Greek debt default will be resolved soon.
07/01/15 - 08:40 AM EDT
American businesses are increasingly taking their money across the Pond, hunting for opportunities to set up shop and turn a profit, a new U.K. government report shows.
07/01/15 - 08:14 AM EDT
The Supreme Court's ruling to keep Obamacare intact was likely a savior for some for-profit hospital systems and could lead to more consolidation for insurance companies and hospital providers.
07/01/15 - 05:59 AM EDT
Stocks staged a comeback as investors bet the Federal Reserve will delay its looming rate hike as Greece moves closer to default.
06/30/15 - 02:43 PM EDT
The number of prescriptions written for MannKind's inhaled insulin drug Afrezza are barely making a dent in the diabetes market five months after partner Sanofi launched the product.
06/30/15 - 11:27 AM EDT
Under terms of the 10-year collaboration, Celgene is buying 9.1 million shares of Juno at $93 per share -- a 102% premium to Juno's closing price of $46.30.
06/29/15 - 05:10 PM EDT